about
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapyKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Current status and unanswered questions on the use of Denosumab in giant cell tumor of boneAdvanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendationsIncidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testingLymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibodyAdvances and controversies in the management of soft tissue sarcomas.Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report.Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view].Research controversies in management of oral mucositis.First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathwaysA dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumoursSorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).Impact of organised programs on colorectal cancer screening.High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults.A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.Trabectedin and its potential in the treatment of soft tissue sarcoma.Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.Angiogenesis inhibition in non-GIST soft tissue sarcomas.Trabectedin for the management of soft-tissue sarcoma.Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for ResEffect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma GroupDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
P50
Q27690653-5F9151F8-243B-4BE7-AC39-FA9A815B971CQ27824868-F3202B44-6A0A-40AC-B7B4-0412999C2E04Q27851824-A9722732-CDD8-4D84-9635-677BAA94F889Q27853199-5F52BA3C-F250-4627-9E74-A2995657B7BBQ28066533-57DD346F-7228-4D80-AB3F-8B71D0D0B45FQ28247449-56B6DBC5-73F7-4F99-8675-D2AD6E41284DQ28741842-C86DB9BB-DDDD-42E7-8DA3-6BBAB05839D6Q28750048-169F8B1A-A161-45BC-846A-D278DFEAF54BQ30240228-00DE5ABC-8A05-4D56-A1BA-A9D8C90912CFQ30409639-4EC0517F-246B-4566-9DE6-DCEB5D3DF67CQ30411362-C777C849-18AA-46A5-87B1-9E6612823FBBQ30491125-47E5A0C2-E82B-447E-A64B-118ABCBF97DEQ30585579-6E94CFBE-F4A4-46E5-A81C-288AD699F71CQ30835090-F711E67E-CF3D-4F96-950E-1C686FB53871Q30896676-84E20B0B-F132-4C27-AB00-55131A8A0936Q30985539-B887802D-FFC5-4AC8-A5A5-DEDE740451C4Q31018689-653D3261-ECF5-4CCD-AF0B-7705AF5A93F9Q31112956-8B5DB23C-FD25-4D67-A3A3-ADFBF0972452Q31165037-95358133-6E85-4887-9A8A-9D3D4897CBDFQ33236909-C885728B-0F4F-4E8A-8CBD-095E2507DFC0Q33274982-581466EA-B861-41A1-B6E7-616341781EFBQ33275688-322226D0-AB7C-4330-8C86-942F2F465BE2Q33276494-1B9D9803-C884-43CD-A4E8-5FAE6507D1D8Q33328300-15028AB5-0B20-4A16-A313-2B2361BD95F7Q33334885-BA6740BF-C4ED-4D00-8AB7-92C40E20D7FEQ33361124-2CB9C34C-7959-4C89-A338-C074A7621498Q33370331-F70D5D54-B1B0-4F61-A4D9-1C45D4142E9AQ33374426-35A4898D-E54D-41A6-AA15-39AE934BF01DQ33380903-56C00193-A395-4952-BA69-12916A183094Q33381250-7250F74A-044E-4C00-8963-C6725E3B380AQ33381641-4B7CDB5A-D79C-49C0-A78F-EB3E78ABFC51Q33382803-27E7F835-5D24-41FF-A3C8-20A56C694723Q33382956-62038386-C983-49BD-B1B7-C3A9C4EFEE1FQ33384836-E8B80CBD-C799-4CC6-91A9-6EAF89ACA47FQ33389572-DC92973A-CBE4-463C-83F7-3B5831616ACDQ33403930-8E46CC52-4462-475D-8730-CC889B41DDB2Q33408040-B26F403B-8226-4271-9A09-3C50B926DFF1Q33409579-140A1D17-ECA1-4BC3-9B7D-66639ECCC5A2Q33413862-02E8B4D9-0791-4462-96E9-E2A592D08916Q33421897-00751814-94D4-479D-A88C-B61B402D3C55
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jean-Yves Blay
@ast
Jean-Yves Blay
@en
Jean-Yves Blay
@es
Jean-Yves Blay
@nl
Jean-Yves Blay
@sl
type
label
Jean-Yves Blay
@ast
Jean-Yves Blay
@en
Jean-Yves Blay
@es
Jean-Yves Blay
@nl
Jean-Yves Blay
@sl
prefLabel
Jean-Yves Blay
@ast
Jean-Yves Blay
@en
Jean-Yves Blay
@es
Jean-Yves Blay
@nl
Jean-Yves Blay
@sl
P214
P244
P1053
N-3966-2016
P106
P21
P213
0000 0000 5519 8721
P214
P244
n2017186001
P31
P3829
P496
0000-0001-7190-120X
P734
P735
P7859
lccn-n2017186001